This company develops HeartDyno, a human cardiac tissue discovery platform, to decode heart function and identify novel drug targets for precision cardiology. The platform integrates functional data with an in silico system, Tempo.ai, to analyze multi-omics data and predict drug safety and efficacy. This engine maps new targets, therapies, and patient populations to advance therapeutic assets for cardiovascular disease.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cardiovascular disease remains the leading cause of mortality, yet current therapies primarily address symptoms and risk factors. The field of precision cardiology lacks well-characterized drug targets and validated therapies using functional human models.
Solution
Dynomics offers HeartDyno®, an engineered human cardiac tissue model designed to decode heart function and power precision cardiac drug discovery. The platform enables the identification of novel drug targets, the discovery of new therapeutics, and the identification of target patient populations. HeartDyno® is a scalable human discovery screening model with authentic cardiac cell composition and function, offering predictive disease models and drug responses. Dynomics also provides Tempo.ai, an _in silico_ platform that integrates HeartDyno® with clinical genomics to enable predictive models of cardiac contractility.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on cardiovascular drug discovery and development.
Features
- Engineered human cardiac tissue model for decoding heart function
- Scalable human discovery screening model
- Authentic cardiac cell composition and function
- Predictive disease models and drug responses
- Tempo.ai _in silico_ platform integrates HeartDyno® with clinical genomics
- Predictive models of cardiac contractility